Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality.

Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr.

Cancer. 2005 Apr 1;103(7):1375-80.

2.

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH.

J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74. Epub 2007 Sep 11.

PMID:
17848668
3.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
4.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

PMID:
17848673
5.

The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.

Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr.

Urol Oncol. 2004 Jul-Aug;22(4):362-8.

PMID:
15283898
6.

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.

Goetzl MA, Holzbeierlein JM.

Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review.

PMID:
16902518
7.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
8.

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?

Mellon JK.

Eur J Cancer. 2005 Sep;41(13):2016-22. Review.

PMID:
16061372
9.

[The pathologist's perspective on the PCPT trial].

Molinié V, Allory Y.

Prog Urol. 2008 Apr;18 Suppl 3:S47-52. doi: 10.1016/S1166-7087(08)70514-1. French.

PMID:
18455084
10.

High-grade prostate cancer and finasteride.

Lebdai S, Bigot P, Azzouzi AR.

BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review.

11.

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.

PMID:
16912265
12.

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.

Cancer. 2008 Mar 1;112(5):1058-65. doi: 10.1002/cncr.23276.

13.

Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?

Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L, Marchand S.

J Urol. 2006 Mar;175(3 Pt 1):934-8; discussion 938.

PMID:
16469585
14.
15.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
16.

[The PCPT trial].

Hamdy FC, Rouprêt M.

Prog Urol. 2008 Apr;18 Suppl 3:S40-3. doi: 10.1016/S1166-7087(08)70512-8. French.

PMID:
18455082
17.

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.

Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD.

Am J Med. 2005 Aug;118(8):850-7.

PMID:
16084177
18.

The cost of prostate cancer chemoprevention: a decision analysis model.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. Erratum in: Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1042.

19.

Update on chemoprevention of prostate cancer.

Klein EA, Thompson IM.

Curr Opin Urol. 2004 May;14(3):143-9. Review.

PMID:
15069304
20.

Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.

Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM.

J Clin Oncol. 2005 Oct 20;23(30):7460-6. Epub 2005 Sep 12.

PMID:
16157937

Supplemental Content

Support Center